Summary
Colorado has recently become the first state to explicitly safeguard neural data privacy, enacting a law on Wednesday, April 17th, 2024. Essentially, this legislation acknowledges that data generated by the nervous system is sensitive.
Supporters in Colorado expressed concerns that without proper safeguards, new devices might enable malicious actors to manipulate an individual's thoughts. Lawmakers in California and Minnesota are similarly evaluating protections for neural data.
Modern healthcare and medical research heavily rely on technology and data. As new technologies emerge, they bring expanded challenges for privacy. The recent move by Colorado demonstrates that regulatory frameworks must remain adaptable and flexible, evolving to cover new scenarios that might not have been envisioned just a few years ago. This is particularly relevant for neurodata and neurotechnology.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Data Protection Strategies for Phase III Clinical Trials
Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.
Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2
Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.
Interview Paul Chilo Director of Governance, Risk & Compliance at SOPHiA GENETICS - SOPHiA UNITY
